Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.
Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser
Viren Morris
Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra region of the brain. This degeneration leads to a range of motor and non-motor symptoms, including tremors, bradykinesia, rigidity, and cognitive impairment. Despite extensive research, the precise etiology of PD remains elusive, involving a combination of genetic and environmental factors. This comprehensive review aims to elucidate the current understanding of the molecular and cellular mechanisms underlying PD pathology, exploring the interplay between genetic mutations, mitochondrial dysfunction, oxidative stress, and inflammation. Accurate diagnosis of PD remains challenging, particularly in the early stages when symptoms may be subtle. We discuss the evolving landscape of diagnostic tools, from clinical assessments to advanced neuroimaging techniques and biomarker discovery. Early and accurate diagnosis is crucial for implementing timely interventions and personalized treatment strategies. The review also addresses the role of emerging technologies, such as artificial intelligence and machine learning, in refining diagnostic precision and predicting disease progression. The treatment landscape for PD has witnessed significant advancements, ranging from traditional pharmacotherapies to innovative neuroprotective and regenerative approaches. Levodopa, the gold standard in PD pharmacotherapy, is discussed in conjunction with adjunct therapies and deep brain stimulation. Additionally, we highlight promising experimental treatments, including gene therapies, stem cell transplantation, and targeted neuroprotective agents, shedding light on their potential to modify disease progression and enhance patient outcomes. The impact of PD extends beyond motor symptoms, encompassing a spectrum of non-motor manifestations that significantly affect patients’ quality of life. This review examines the diverse array of non-motor symptoms, including autonomic dysfunction, sleep disturbances, and psychiatric complications. A comprehensive understanding of these aspects is crucial for holistic patient management and the development of targeted interventions.